3Q16 Financial Results and Program Updates 2016

Amgen's third-quarter 2016 earnings presentation delivered November 7, 2016, covering Galafold international launch, clinical trial updates for Pompe and epidermolysis bullosa, and regulatory progress on migalastat. The company focuses on rare and devastating diseases with strategic priorities including balance sheet strength and pipeline development.</description> <parameter name="content_type">earnings